Literature DB >> 31938282

Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines.

Yong Zhang1, Nan Ding1,2, Yunfeng Cao3,4,5, Zhitu Zhu3,6, Peng Gao1,2,3.   

Abstract

The routine biochemical parameters for hepatocellular carcinoma (HCC) diagnosis are all protein markers. Serum concentrations of these markers can be affected by some benign diseases. Most of the occurrence of HCC has a background of cirrhosis, posing a great challenge to differential diagnosis of HCC from cirrhosis using traditional biochemical parameters. Values of serum small molecular metabolites for HCC diagnosis are not fully evaluated. In this study, a traditionalmass spectrometry-based screening strategy was employed to profile amino acids and acylcarnitines in blood samples collected from HCC and cirrhosis patients. Each whole blood specimen was sampled on filter paper and dried at room temperature. Metabolites in the dried blood spots were extracted using organic solvent and then concentrated for mass spectrometry analysis. It was found that 11 parameters, including amino acids, acylcarnitines and some of their relevant ratios, could be used to construct a satisfied differential diagnosis model. In this model, most of the relevant amino acids were essential amino acids. It was noticed that short-chain acylcarnitines tended to be risk factors for HCC. Long-chain acylcarnitines seemed to be risk factors for cirrhosis. This study demonstrates the value of mass spectrometry-based analysis for differential diagnosis of HCC and cirrhosis. Improved differential diagnosis ability may be achieved by combined use of traditional protein markers along with metabolite markers. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Hepatocellular carcinoma; amino acids; carnitine; mass spectrometry

Year:  2018        PMID: 31938282      PMCID: PMC6958111     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

Review 1.  Effective Use of Mass Spectrometry in the Clinical Laboratory.

Authors:  Paul J Jannetto; Robert L Fitzgerald
Journal:  Clin Chem       Date:  2015-11-09       Impact factor: 8.327

Review 2.  Alpha-fetoprotein, a fascinating protein and biomarker in neurology.

Authors:  J H Schieving; M de Vries; J M G van Vugt; C Weemaes; M van Deuren; J Nicolai; R A Wevers; M A Willemsen
Journal:  Eur J Paediatr Neurol       Date:  2013-09-29       Impact factor: 3.140

Review 3.  Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma.

Authors:  Chloé Sauzay; Alexandra Petit; Anne-Marie Bourgeois; Jean-Claude Barbare; Bruno Chauffert; Antoine Galmiche; Aline Houessinon
Journal:  Clin Chim Acta       Date:  2016-10-11       Impact factor: 3.786

4.  Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study.

Authors:  Shunichi Shiozawa; Takebumi Usui; Kotaro Kuhara; Akira Tsuchiya; Tatsuomi Miyauchi; Teppei Kono; Shinichi Asaka; Kentaro Yamaguchi; Hajime Yokomizo; Takeshi Shimakawa; Kazuhiko Yoshimatsu; Takao Katsube; Yoshihiko Naritaka
Journal:  J Nippon Med Sch       Date:  2016       Impact factor: 0.920

Review 5.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

6.  Recent topics on α-fetoprotein.

Authors:  Kazuhiko Nakao; Tatsuki Ichikawa
Journal:  Hepatol Res       Date:  2013-01-25       Impact factor: 4.288

Review 7.  Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer.

Authors:  Nicole J Ullrich
Journal:  Dev Disabil Res Rev       Date:  2008

8.  Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.

Authors:  J-W Liu; X-L Zuo; S Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-10       Impact factor: 3.507

Review 9.  Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer.

Authors:  Q Qu; F Zeng; X Liu; Q J Wang; F Deng
Journal:  Cell Death Dis       Date:  2016-05-19       Impact factor: 8.469

10.  A neonatal case of 3-hydroxy-3-methylglutaric-coenzyme A lyase deficiency.

Authors:  Francesca Santarelli; Michela Cassanello; Ausilia Enea; Francesca Poma; Valentina D'Onofrio; Giovanna Guala; Giangiacomo Garrone; Paola Puccinelli; Ubaldo Caruso; Francesco Porta; Marco Spada
Journal:  Ital J Pediatr       Date:  2013-05-24       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.